Table I:
Baseline characteristics in HPV-associated OPSCC stratified by race
| Race | White | Black | |||
|---|---|---|---|---|---|
| No. | % | No. | % | P-value | |
| Age | P=0.008 | ||||
| Age < 50 (n=52) | 49 | 34% | 3 | 27% | |
| Age 50 – 65 (n=84) | 76 | 52% | 8 | 73% | |
| Age 65+ (n=21) | 21 | 14% | 0 | 0% | |
| 146 | 100% | 11 | 100% | ||
| Sex | P = 0.997 | ||||
| Male (n=129) | 120 | 82% | 9 | 82% | |
| Female (n=28) | 26 | 18% | 2 | 18% | |
| 146 | 100% | 11 | 100% | ||
| Education | P = 0.086 | ||||
| Less than high school (n=25) | 22 | 15% | 3 | 27% | |
| High school graduate (n=41) | 35 | 24% | 6 | 55% | |
| Education past high school (n=91) | 89 | 61% | 2 | 18% | |
| 146 | 100% | 11 | 100% | ||
| Insurance (relative to private) | P = 0.118 | ||||
| Private insurance (n=93) | 90 | 62% | 3 | 27% | |
| Medicaid/Medicare (n=24) | 21 | 14% | 3 | 27% | |
| No insurance (n=18) | 15 | 10% | 3 | 27% | |
| Other insurance (n=22) | 20 | 14% | 2 | 18% | |
| 146 | 100% | 11 | 100% | ||
| Income | P=0.001 | ||||
| Income > $50,000 (n=75) | 75 | 53% | 0 | 0% | |
| Income $20,000 – $50,000 (n=49) | 45 | 32% | 4 | 36% | |
| Income < $20,000 (n=29) | 22 | 15% | 7 | 64% | |
| 142 | 100% | 11 | 100% | ||
| Rural/Urban Household | P=0.536 | ||||
| Metropolitan (n=90) | 85 | 81% | 5 | 62% | |
| Micropolitan (n=11) | 10 | 10% | 1 | 12% | |
| Rural (n=12) | 10 | 10% | 2 | 25% | |
| 105 | 100% | 8 | 100% | ||
| Driving Time to clinic where biopsy was performed (1st quartile as baseline) | P=0.049 | ||||
| 1st quartile (n=20) | 20 | 20% | 0 | 0% | |
| 2nd quartile (n=31) | 30 | 30% | 1 | 14% | |
| 3rd quartile (n=27) | 26 | 26% | 1 | 14% | |
| 4th quartile (n=30) | 25 | 25% | 5 | 71% | |
| 101 | 100% | 7 | 100% | ||
| Smoking (>10 pack-years) | P=0.228 | ||||
| < 10 Pack Years (n=66) | 64 | 44% | 2 | 18% | |
| > 10 Pack Years (n=90) | 81 | 56% | 9 | 82% | |
| 145 | 100% | 11 | 100% | ||
| Alcohol use | P=0.087 | ||||
| None (n=25) | 24 | 17% | 1 | 10% | |
| Any (n=130) | 121 | 83% | 9 | 90% | |
| 145 | 100% | 10 | 100% | ||
| T Stage | P=0.173 | ||||
| T1 (n=43) | 41 | 28% | 2 | 18% | |
| T2 (n=68) | 66 | 45% | 2 | 18% | |
| T3 (n=24) | 20 | 14% | 4 | 36% | |
| T4 (n=22) | 19 | 13% | 3 | 27% | |
| 146 | 100% | 11 | 100% | ||
| Early (1–2) vs. Advanced T Stage (3–4) | P=0.027 | ||||
| Early T Stage (n=111) | 107 | 73% | 4 | 36% | |
| Advanced T Stage (n=46) | 39 | 27% | 7 | 64% | |
| 146 | 100% | 11 | 100% | ||
| N stage | P=0.857 | ||||
| N0 (n=29) | 26 | 18% | 3 | 27% | |
| N1 (n=93) | 88 | 60% | 5 | 45% | |
| N2 (n=20) | 18 | 12% | 2 | 18% | |
| N3 (n=15) | 14 | 10% | 1 | 9% | |
| 146 | 100% | 11 | 100% | ||
| M Stage | P=0.889 | ||||
| M0 (n=155) | 144 | 99% | 11 | 100% | |
| M1 (n=2) | 2 | 1% | 0 | 0% | |
| 146 | 100% | 11 | 100% | ||
| Treatment Category | P=0.805 | ||||
| Chemotherapy Only (n=1) | 1 | 1% | 0 | 0% | |
| Radiation Only (n=11) | 10 | 7% | 1 | 9% | |
| Surgery Only (n=7) | 7 | 5% | 0 | 0% | |
| Radiation + Chemotherapy (n=61) |
54 | 37% | 7 | 64% | |
| Surgery + Radiation (n=36) | 34 | 23% | 2 | 18% | |
| Surgery + | 40 | 27% | 1 | 9% | |
| Chemoradiation (n=41) | 146 | 100% | 11 | 100% | |
| Number of Treatment Modalities | 0.472 | ||||
| 1 (n=19) | 18 | 12% | 1 | 9% | |
| 2 (n=97) | 88 | 60% | 9 | 82% | |
| 3 (n=41) | 40 | 27% | 1 | 9% | |
| 146 | 100% | 11 | 100% | ||